Dual CAR (CD19/CD20) Program
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Pre-clinicalActive
Key Facts
Indication
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase
Pre-clinical
Status
Active
Company
About CPTx
Founded in 2020 in Munich, CPTx is a private, pre-clinical biotech developing in vivo CAR-T therapies using a proprietary non-viral platform. Its technology combines long, high-fidelity ssDNA constructs with LNP delivery to enable immune-silent, tunable, and repeatable dosing, aiming to democratize cell therapy. The lead program targets CD19/CD20 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with a broader vision to expand into other cancers and autoimmune diseases. The company operates with an integrated model, controlling platform development, pipeline advancement, and in-house ssDNA manufacturing.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Drugs
| Drug | Company | Phase |
|---|---|---|
| Maveropepimut-S (MVP-S) + Pembrolizumab | BioVaxys | Phase 2 |